Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
Authors
Keywords
-
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-19
DOI
10.1007/s11060-020-03598-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
- (2020) Nina Struve et al. ONCOGENE
- Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
- (2019) Paul Daniel et al. Frontiers in Oncology
- Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
- (2019) Denise Fabian et al. Cancers
- Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
- (2019) Aida Karachi et al. NEURO-ONCOLOGY
- Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
- (2019) Sabrina Heynckes et al. BMC CANCER
- Temozolomide-associated hypermutation in gliomas
- (2018) Serah Choi et al. NEURO-ONCOLOGY
- Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
- (2018) Carter M. Suryadevara et al. OncoImmunology
- Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma
- (2018) Stefano Indraccolo et al. CLINICAL CANCER RESEARCH
- Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy
- (2017) Alexander J. Lin et al. JOURNAL OF NEURO-ONCOLOGY
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
- (2017) D. A. Reardon et al. NEURO-ONCOLOGY
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Clonal evolution of glioblastoma under therapy
- (2016) Jiguang Wang et al. NATURE GENETICS
- Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
- (2016) Guido Bocci et al. Nature Reviews Clinical Oncology
- Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide
- (2016) Michael Wahl et al. NEURO-ONCOLOGY
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment
- (2015) Hinke F. van Thuijl et al. ACTA NEUROPATHOLOGICA
- Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?
- (2015) Martha R Neagu et al. Immunotherapy
- A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
- (2015) Aleksanteri Aspelund et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis
- (2015) Grit Welzel et al. JOURNAL OF NEURO-ONCOLOGY
- Immunosuppressive mechanisms in glioblastoma: Fig. 1.
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
- (2014) P. E. Fecci et al. CLINICAL CANCER RESEARCH
- Vaccine therapies for patients with glioblastoma
- (2014) Eli T. Sayegh et al. JOURNAL OF NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
- (2014) Q. T. Ostrom et al. NEURO-ONCOLOGY
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
- (2014) Daniel J. Ma et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas
- (2014) Chul-Kee Park et al. Translational Oncology
- Has the time come for metronomics in low-income and middle-income countries?
- (2013) Nicolas André et al. LANCET ONCOLOGY
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas
- (2012) Catherine A Del Vecchio et al. Expert Review of Vaccines
- A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
- (2012) John H. Sampson et al. PLoS One
- A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid
- (2012) J. J. Iliff et al. Science Translational Medicine
- Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans
- (2011) D. A. Mitchell et al. BLOOD
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
- (2011) Jörg Felsberg et al. INTERNATIONAL JOURNAL OF CANCER
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
- (2011) C. E. Fadul et al. NEURO-ONCOLOGY
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Dose-dense temozolomide regimens
- (2010) Bart Neyns et al. CANCER
- IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas
- (2010) Bo Qiu et al. MOLECULAR BIOLOGY REPORTS
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
- (2009) Claire Banissi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model
- (2009) T.-G. Kim et al. Clinical and Vaccine Immunology
- Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
- (2007) Amy B. Heimberger et al. NEURO-ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started